Edwards Lifesciences Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 23, 2026.
Q2 2026
EPS
$0.78
est $0.74
+5.1%
Revenue
$1.74B
est $1.70B
+2.4%
Edwards Lifesciences beat Q2 earnings on the back of a 48% surge in mitral and tricuspid therapies, and raised full-year sales guidance to 10%-11% growth as TAVR durability data and a pending Medicare decision unlock new patient pools.
Mentioned: EW